KEY TAKEAWAYS
- Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.
- The new firm will have a pro forma enterprise value of $6.7 billion.
- Both drugmakers have emerged from bankruptcies in recent years and dealt with litigation related to their production of opioids.
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange (NYSE), the two drugmakers said Thursday.
Under the terms of the agreement, shareholders of Malvern, Pa.-based Endo will receive $80 million in cash and own 49.9% of the combined firm. Mallinckrodt will be the holding company for the combined company with a pro forma enterprise value of $6.7 billion, and its shareholders will control 50.1%.
The companies plan to combine their generic pharmaceuticals operations with Endo’s sterile injectables business once the merger is complete and separate that unit “at a later date.” The merger, which has been approved by both boards, is expected to close in the second half of 2025.
“We believe this combination with Mallinckrodt, along with the subsequent separation of the combined sterile injectables and generics business, presents a unique opportunity to deliver significant shareholder value,” Endo interim CEO Scott Hirsch said.
Both firms have emerged from bankruptcy in recent years. They have also dealt with litigation related to their production of opioids.
:max_bytes(150000):strip_icc()/GettyImages-1621998297-b90d017d68fd4d63acfb19e01d5b3f0f.jpg?w=1200&resize=1200,0&ssl=1&description=Drugmakers+Mallinckrodt%2C+Endo+to+Merge%2C+Plan+NYSE+Listing){kind=link}